Engineering a controllable and reversible switch for CAR-based cellular immunotherapies via a genetic code expansion system.

ABSTRACT:

Background

As one of the most promising adoptive cell therapies, CAR-T cell therapy has achieved notable clinical effects in patients with hematological tumors. However, several treatment-related obstacles remain in CAR-T therapy, such as cytokine release syndrome, neurotoxicity, and high-frequency recurrence, which severely limit the long-term effects and can potentially be fatal. Therefore, strategies to increase the controllability and safety of CAR-T therapy are urgently needed.

Methods

In this study, we engineered a genetic code expansion-based therapeutic system to achieve rapid CAR protein expression and regulation in response to cognate unnatural amino acids at the translational level. When the unnatural amino acid N-ε-((tert-butoxy) carbonyl)-l-lysine (BOCK) is abse

SUBMITTER: Liu Y 

PROVIDER: S-EPMC11657976 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature